Friday, 15 Dec 2017

You are here

RheumNow Week in Review – 14 October 2015

Dr Jack Cush reviews highlights from the news and journal articles appearing this week on RheumNow.com:

  1. Prevalence of noninfectious uveitis in USA: Nearly 300,000 adults and 22,000 children in 2015 (based on claims data). http://buff.ly/2e7ew4y
  2. Global biosimilars sales = 3.5 billion in 2015; poised to reach $15.6 billion by 2022. https://t.co/TATv2rgYTM
  3. Patients with VERY high levels of CRP & nonspecific findings should raise suspicion for other non-rheumatic diagnoses (infection, malignancy). https://t.co/xbCTGXPd5L
  4. Medicare study shows no increased risk of breast cancer in RA or IBD women taking MTX, 6MP or TNF inhibitors! https://t.co/lHyUbyjNCQ
  5. Norwegian HUNT study shows no increased risk of fracture among 2804 self reported psoriasis patients. https://t.co/PHNMUac27A
  6. High ESR/CRP in a Rheumatology Hospital: Rheumatic diseases were most common (52%); lead by PMR (38%), seronegative RA, infection (25%), neoplasia (9%). https://t.co/9mkJhQMXwZd
  7. Diabetes has frequent articular and periarticular findings: including OA knee (most common at 49%), carpal tunnel syndrome (29%), frozen shoulder (23%), cheiroarthropathy (16%). https://t.co/pGRNI6wQTQ
  8. Metanalysis: ankle replacement (TAA) vs arthrodeisis w/ similar outcomes but more reoperations, complications w/ TAA. https://t.co/dGbZLl28mi
  9. Phase II ACCLAIM small trial fails to show significant benefit/safety of Abatacept in multiple sclerosis (42 pts). https://t.co/GeU5XnhePt
  10. Endocannabinoid, Resunab (JBT-101), in a clinical trial for scleroderma. It decreases TGF-B & collagen. https://t.co/Iu8OLPm5BC
  11. Mayo study of incident Sarcoidosis shows 3 fold higher risk of venous thrombosis & 4 fold risk of pulm embolism. https://t.co/C4gZc951aJ
  12. My Take on New Ocular Screening Guidelines for Plaquenil 
  13. 1/3 of First Degree Relatives to AS patients are at Risk of Spondyloarthritis
  14. New Criteria for the Cryopyrinopathies (CAPS)
  15. Long-Term Outcomes of Aromatase Inhibitor Arthralgias
Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

The RheumNow Week in Review - 8 December 2017

Dr. Jack Cush covers the news and journal articles published on RheumNow.comin the past week.

Rheumatology Year in Review

During 2017, the improvements and refinements seen during previous years in the treatment of rheumatoid arthritis have been extending to other conditions ranging from psoriatic arthritis to lupus and for both monoclonal antibodies and oral small molecule medications.

Advances for Biologics

The ACR17 RheumNow Week in Review - 1 December 2017

Dr Jack Cush reviews nighlights and news from the past 2 weeks on RheumNow.com. This week's report includes new drug approvals, disappointing ACR guidelines, Lyme & Zika, infertility, dermatomyositis skin outcomes and myositis-associated cancer testing.

ACR Clinical Guidelines Flawed by Low Evidence

JAMA Internal Medicine has reported that recommendations and clinical practice guidelines from the American College of Rheumatology are often based on expert opinion, but lack rigorous (grade A) evidence to support many of their recommendations. 

RheumNow ACR 2017 Awards

The Annual Meeting of the American College of Rheumatology is a gargantuan educational and professional event that is on nearly everyone's radar each year. RheumNow had an expansive effort to cover this meeting and you can review the work of our faculty at ACR17.RheumNow.com.  But we have decided to take this one step further and today we are announcing our 2017 RheumNow ACR Awards.